Research progression on the first-line biological target therapy of advanced
DOI：10.3872/j.issn.1007-385x.2020.08.002
- VernacularTitle:晚期非小细胞肺癌一线生物靶向治疗的研究进展
- Author:
JIANG Zhansheng
1
;
ZHANG Yu
1
;
REN Xiubao
2
,
3
;
PAN Zhanyu
1
Author Information
1. Department of Integrated Chinese and Western Medicine
2. b. Depart‐ ment of Biotherapy and Biotechnology Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin&rsquo
3. s Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy (Tianjin), Tianjin 300060, China
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
advanced stage;
first-line treatment;
targeted therapy;
immunotherapy
- From:
Chinese Journal of Cancer Biotherapy
2020;27(8):843-851
- CountryChina
- Language:Chinese
-
Abstract:
With the progress of gene detection technology and the speed-up in new drug development, biological target therapy has fully covered the first-line treatment of advanced NSCLC. Immunotherapy has significantly improved the survival of advanced NSCLC patients with negative driven genes, and the median OS reaches about 2 years (15.6-30 months). EGFR is the most common driven
gene. According to different EGFR mutation subtypes (L858R or 19del), different treatment mode (EGFR-TKI single drug, TKI combined with anti-vascular drugs and TKI combined with chemotherapy) is selected as the first-line treatment, which has become a consensus. Depending on the data of median PFS, the treatment efficacy against rare targets is more prominent, which has exceeded the efficacy of standard chemotherap:ALK (alectinib, PFS=34.8 months), ROS1 (ceritinib, PFS=19.3 months), RET (selpercatinib, PFS=18.4 months), BRAF (dabrafenib plus trametinib, PFS=14.6 months), NTRK (larotrectinib, PFS≥12 months) and MET (savolitinib, PFS=9.7
months). In conclusion, the first-line treatment of advanced NSCLC has entered the era of“precision-targeted treatment”based on
different molecular typing, and it has become a consensus that high-throughput sequencing is required for newly diagnosed patients.
- Full text:20200802.pdf
